PMA device
MiniMed 670G System
Medtronic Minimed, Inc. · Automated Insulin Dosing Device System, Single Hormonal Control (OZP, Class III) · First FDA decision Sep 28, 2016, newest Dec 18, 2025Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
12
Breakthrough-designated
Device trials
12
Naming "MiniMed 670G"
MAUDE reports
91
Brand "MiniMed 670G", since 2015
PubMed studies
92
Mentioning "MiniMed 670G"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MiniMed 670G System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 12 decisions filed under this name.
- MiniMed 670G SystemPMA supplement
P160017-S133 · Decided Dec 18, 2025 · 23 days after receipt · Normal 180 Day Track No User Fee
Device type: Automated insulin dosing device system, single hormonal control (OZP) · Laboratory Medicine & Pathology
- MiniMed 670G Pump, MiniMed 770G Pump, Guardian Link (3) Transmitter, Guardian Sensor (3), Contour Next Link 2.4 Meter, RPMA supplement
P160017-S117 · Decided Mar 21, 2024 · 34 days after receipt · Normal 180 Day Track No User Fee
Device type: Automated insulin dosing device system, single hormonal control (OZP) · Laboratory Medicine & Pathology
- MiniMed 670G System, MiniMed 770G SystemPMA supplement
P160017-S089 · Decided Apr 19, 2021 · 123 days after receipt · Normal 180 Day Track No User Fee
Device type: Automated insulin dosing device system, single hormonal control (OZP) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P160017-S027, P160017-S020, P160017-S017, P160017-S004, P160017-S003, P160017
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "MiniMed 670G", any status and sponsor, newest update first.
- The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMsActive, not recruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT04414280 · 1,600 participants (planned) · Start Mar 12, 2020 · Primary completion Apr 2028
Device: Medtronic MiniMed 670G; Medtronic MiniMed 780G and 2 more · For: Diabetes Mellitus, Type 1
Sites: Leuven, Belgium; Aalst, Belgium; Antwerp, Belgium · 38 sites in all
- Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at HomePivotal-lookingCompleted
Medtronic MiniMed, Inc.Public (MDT)
NCT02748018 · 959 participants · Start May 25, 2017 · Primary completion Nov 1, 2023
Device: 670G and 770G Insulin Pump; Subject's Current Diabetes Therapy · For: Type 1 Diabetes
Sites: La Jolla, California; Palo Alto, California; Sacramento, California · 36 sites in all
University of PennsylvaniaAcademic, hospital or other
NCT03215914 · 10 participants · Start Aug 1, 2017 · Primary completion May 31, 2022
Device: MiniMed 670G system · For: Type1diabetes; Hypoglycemia Unawareness; Nocturnal Hypoglycemia and 2 more
Sites: Philadelphia, Pennsylvania · 3 sites in all
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MiniMed 670G", and for the whole product code for context.
This brand
91 reports: 35 malfunction, 55 injury, 1 death
Whole product code OZP
911,539 reports: 781,296 malfunction, 128,965 injury, 1,268 death
Newest reports for this brand
MEDTRONIC PUERTO RICO OPERATIONS CO.
2032227-2026-101252 · Received Jan 5, 2026 · Event dated Dec 3, 2025
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hyperglycemia
- MINIMED 670GInjury
MW5172119 · Received Jun 30, 2025 · Event dated Jun 12, 2025
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Failure to Pump; Defective Device
Patient problem as coded: Hyperglycemia
- MINIMED 670G INSULIN PUMP KIT 3.0 MLMalfunction
2032227-2025-188794 · Received Jun 10, 2025 · Event dated May 15, 2025
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Mechanical Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782;Open, Classified
Z-2981-2026 · Started Jul 13, 2026 · Posted by FDA Aug 18, 2026
Reason given: Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis.
Cause as FDA categorized it: Process design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
- MiniMed 670G Insulin Pump (MMT-1760, MMT-1761, MMT-1762, MMT-1780, MMT-1781, MMT-1782)Open, Classified
Z-1739-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
- MiniMed 770G Insulin Pump (MMT-1880, MMT-1881, MMT-1882, MMT-1890, MMT-1891, MMT-1892)Open, Classified
Z-1742-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
11 more recall records with a free account
Published research
The most relevant PubMed records for "MiniMed 670G"[tiab]. The summary above synthesizes these.
- Medtronic MiniMed 670G Hybrid Closed-Loop System.
Knebel T, Neumiller JJ · Clin Diabetes · 2019
- Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis.
Di Molfetta S, Di Gioia L, Caruso I, et al. · Diabetes Metab Res Rev · 2024Systematic Review, Network Meta-Analysis
- Real-world performance of the MiniMedࡊ 670G system in Europe.
Da Silva J, Bosi E, Jendle J, et al. · Diabetes Obes Metab · 2021Research Support, Non-U.S. Gov't
- Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. · Diabetes Technol Ther · 2019Evaluation Study, Research Support, Non-U.S. Gov't
- Commercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy.
Moreno-Fernández J, García-Seco JA · AACE Clin Case Rep · 2021Case Reports
- Minimed 670G: a hybrid closed-loop insulin delivery system.
Med Lett Drugs Ther · 2016Review
- THE MINIMEDࡊ 670G HYBRID AUTOMATED INSULIN DELIVERY SYSTEM: SETTING THE RIGHT EXPECTATIONS.
Leelarathna L, Thabit H · Endocr Pract · 2018
- Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J, Pöhlmann J, de Portu S, et al. · Diabetes Technol Ther · 2019Comparative Study, Research Support, Non-U.S. Gov't
- Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study.
Jacobsen SS, Hommel E, Ranjan AG, et al. · Diabetes Technol Ther · 2022Observational Study
- An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance.
Horowitz ME, Kaye WA, Pepper GM, et al. · Diabetes Res Clin Pract · 2021
- Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
Mameli C, Smylie GM, Galati A, et al. · Eur J Pediatr · 2023Systematic Review
- MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy.
Saunders A, Messer LH, Forlenza GP · Expert Rev Med Devices · 2019Review
Other devices of this type
Also filed under product code OZP.
- MiniMed 780G SystemMedtronic Minimed, Inc. · PMA 2026
- MiniMed 770G SystemMedtronic Minimed, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.